Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: A Gynecologic Oncology Group phase II study

Randomized Phase II Study of Gemcitabine and Docetaxel Compared With Gemcitabine Alone in Patients With Metastatic Soft Tissue Sarcomas: Results of Sarcoma Alliance for Research Through Collaboration Study 002

2007 • 682 citations

Gemcitabine and Docetaxel in Patients With Unresectable Leiomyosarcoma: Results of a Phase II Trial

2002 • 670 citations

Prognostic factors in early‐stage uterine sarcoma: A gynecologic oncology group study

1993 • 637 citations

Phase II Study of Sorafenib in Patients With Metastatic or Recurrent Sarcomas

2009 • 551 citations

Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.

1995 • 519 citations

Randomized Phase II Comparison of Dose-Intense Gemcitabine: Thirty-Minute Infusion and Fixed Dose Rate Infusion in Patients With Pancreatic Adenocarcinoma

2003 • 512 citations

Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas

2002 • 416 citations

Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: A Gynecologic Oncology Group phase II study

2008 • 359 citations

A randomized study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas

1983 • 352 citations

Ifosfamide and Doxorubicin in the Treatment of Advanced Leiomyosarcomas of the Uterus: A Gynecologic Oncology Group Study

1996 • 211 citations

Pharmacologically directed design of the dose rate and schedule of 2',2'-difluorodeoxycytidine (Gemcitabine) administration in leukemia.

1990 • 208 citations

Ecteinascidin-743 (ET-743) for Chemotherapy-Naive Patients With Advanced Soft Tissue Sarcomas: Multicenter Phase II and Pharmacokinetic Study

2005 • 191 citations

Docetaxel and gemcitabine combination in 133 advanced soft‐tissue sarcomas: A retrospective analysis

2006 • 175 citations

Ecteinascidin-743: A Marine-Derived Compound in Advanced, Pretreated Sarcoma Patients—Preliminary Evidence of Activity

2001 • 168 citations

Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) Study

2004 • 161 citations

Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent uterine sarcomas: a Gynecologic Oncology Group study.

1991 • 159 citations

Phase II trial of ifosfamide and mesna in leiomyosarcoma ofthe uterus: A Gynecologic Oncology Group study

1992 • 150 citations

Optimal flexible designs in phase II clinical trials

1998 • 120 citations

Resection of pulmonary metastases from uterine sarcomas

1992 • 104 citations

A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: A Gynecologic Oncology Group study

2007 • 90 citations

A phase II trial of temozolomide as a 6‐week, continuous, oral schedule in patients with advanced soft tissue sarcoma

2005 • 88 citations

Phase II Trial of Paclitaxel in Leiomyosarcoma of the Uterus: A Gynecologic Oncology Group Study

1999 • 85 citations

Evaluation of paclitaxel in previously treated leiomyosarcoma of the uterus: a gynecologic oncology group study

2003 • 82 citations

High incidence of pulmonary toxicity of weekly docetaxel and gemcitabine in patients with non-small cell lung cancer: results of a dose-finding study

2004 • 66 citations

Prolonged Oral Etoposide in Recurrent or Advanced Leiomyosarcoma of the Uterus: A Gynecologic Oncology Group Study

1998 • 65 citations

Soft Tissue Sarcoma Guidelines

2007 • 64 citations

Clinical features and correlates of gemcitabine‐associated lung injury

2006 • 61 citations

Phase II Trial of Topotecan in Patients With Advanced, Persistent, or Recurrent Uterine Leiomyosarcomas

2000 • 57 citations

Cisplatin as Second-Line Chemotherapy in the Treatment of Advanced or Recurrent Leiomyosarcoma of the Uterus A Phase II Trial of the Gynecologic Oncology Group

1986 • 55 citations

Combination Chemotherapy with Hydroxyurea, Dacarbazine (DTIC), and Etoposide in the Treatment of Uterine Leiomyosarcoma: A Gynecologic Oncology Group Study

1996 • 46 citations

Trimetrexate in the Treatment of Recurrent or Advanced Leiomyosarcoma of the Uterus: A Phase II Study of the Gynecologic Oncology Group

2002 • 44 citations

Mitoxantrone in the Treatment of Advanced Uterine Sarcoma

1990 • 39 citations

Phase II trial of etoposide in the management of advanced and recurrent leiomyosarcoma of the uterus: a Gynecologic Oncology Group Study.

1987 • 35 citations

Clinical results of a phase II study of sorafenib in patients (pts) with non-GIST sarcomas (CTEP study #7060)

2007 • 29 citations

Docetaxel in Combination with Either Cisplatin or Gemcitabine in Unresectable Non-small Cell Lung Carcinoma: A Randomized Phase II Study by the Japan Lung Cancer Cooperative Clinical Study Group

2006 • 25 citations

ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of soft tissue sarcomas

2005 • 24 citations

Fatal Interstitial Pneumonitis Associated with Docetaxel Administration in a Patient with Hormone-Refractory Prostate Cancer

2006 • 19 citations

A phase II clinical trial of diaziquone (AZQ) in the treatment of patients with recurrent leiomyosarcoma of the uterus

1991 • 18 citations

Amonafide in Patients With Leiomyosarcoma of the Uterus

1998 • 18 citations

Docetaxel in Combination with Either Cisplatin or Gemcitabine in Unresectable Non-small Cell Lung Carcinoma: A Randomized Phase II Study by the Japan Lung Cancer Cooperative Clinical Study Group

2006 • 15 citations

Severe pulmonary toxicity in patients with leiomyosarcoma after treatment with gemcitabine and docetaxel

2007 • 7 citations

Cited By (0)

No citing papers found in database